Terms: = Breast cancer AND PAM50
443 results:
1. Bioinformatics analysis of the potentially functional circRNA-miRNA-mRNA network in breast cancer.
Erdogan C; Suer I; Kaya M; Ozturk S; Aydin N; Kurt Z
PLoS One; 2024; 19(4):e0301995. PubMed ID: 38635539
[TBL] [Abstract] [Full Text] [Related]
2. Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.
Bartoloni S; Pescatori S; Bianchi F; Cipolletti M; Acconcia F
Sci Rep; 2024 Apr; 14(1):8200. PubMed ID: 38589728
[TBL] [Abstract] [Full Text] [Related]
3. Molecular subtyping improves breast cancer diagnosis in the Copenhagen breast cancer Genomics Study.
Berg T; Jensen MB; Celik A; Talman ML; Misiakou MA; Knoop AS; Nielsen FC; Ejlertsen B; Rossing M
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587073
[TBL] [Abstract] [Full Text] [Related]
4. BIRC5 expression by race, age and clinical factors in breast cancer patients.
Hamilton AM; Walens A; Van Alsten SC; Olsson LT; Nsonwu-Farley J; Gao X; Kirk EL; Perou CM; Carey LA; Troester MA; Abdou Y
Breast Cancer Res; 2024 Mar; 26(1):50. PubMed ID: 38515208
[TBL] [Abstract] [Full Text] [Related]
5. Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
Ren H; Wang Z; Zhang L; Zhu G; Li F; Chen B
BMC Cancer; 2024 Mar; 24(1):367. PubMed ID: 38515057
[TBL] [Abstract] [Full Text] [Related]
6. Caveolin-1 gene expression provides additional prognostic information combined with pam50 risk of recurrence (ROR) score in breast cancer.
Godina C; Belting M; Vallon-Christersson J; Isaksson K; Bosch A; Jernström H
Sci Rep; 2024 Mar; 14(1):6675. PubMed ID: 38509243
[TBL] [Abstract] [Full Text] [Related]
7. Modelling-based joint embedding of histology and genomics using canonical correlation analysis for breast cancer survival prediction.
Subramanian V; Syeda-Mahmood T; Do MN
Artif Intell Med; 2024 Mar; 149():102787. PubMed ID: 38462287
[TBL] [Abstract] [Full Text] [Related]
8. Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindström LS; Tobin NP
Breast Cancer Res; 2024 Mar; 26(1):38. PubMed ID: 38454481
[TBL] [Abstract] [Full Text] [Related]
9. B-Cell-Mediated Immunity Predicts Survival of Patients With Estrogen Receptor-Positive breast cancer.
Lee S; Kang BH; Lee HB; Jang BS; Han W; Kim IA
JCO Precis Oncol; 2024 Mar; 8():e2300263. PubMed ID: 38452311
[TBL] [Abstract] [Full Text] [Related]
10. Few-shot genes selection: subset of pam50 genes for breast cancer subtypes classification.
Okimoto LYS; Mendonca-Neto R; Nakamura FG; Nakamura EF; Fenyö D; Silva CT
BMC Bioinformatics; 2024 Mar; 25(1):92. PubMed ID: 38429657
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Characterization and Subtyping of breast cancer Cell Lines Provide Novel Insights into cancer Relevant Genes.
Pommerenke C; Nagel S; Haake J; Koelz AL; Christgen M; Steenpass L; Eberth S
Cells; 2024 Feb; 13(4):. PubMed ID: 38391914
[TBL] [Abstract] [Full Text] [Related]
12. NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.
Mendiburu-Eliçabe M; García-Sancha N; Corchado-Cobos R; Martínez-López A; Chang H; Hua Mao J; Blanco-Gómez A; García-Casas A; Castellanos-Martín A; Salvador N; Jiménez-Navas A; Pérez-Baena MJ; Sánchez-Martín MA; Abad-Hernández MDM; Carmen SD; Claros-Ampuero J; Cruz-Hernández JJ; Rodríguez-Sánchez CA; García-Cenador MB; García-Criado FJ; Vicente RS; Castillo-Lluva S; Pérez-Losada J
Clin Transl Med; 2024 Feb; 14(2):e1554. PubMed ID: 38344872
[TBL] [Abstract] [Full Text] [Related]
13. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative breast cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
Ma CX; Suman VJ; Sanati S; Vij K; Anurag M; Leitch AM; Unzeitig GW; Hoog J; Fernandez-Martinez A; Fan C; Gibbs RA; Watson MA; Dockter TJ; Hahn O; Guenther JM; Caudle A; Crouch E; Tiersten A; Mita M; Razaq W; Hieken TJ; Wang Y; Rimawi MF; Weiss A; Winer EP; Hunt KK; Perou CM; Ellis MJ; Partridge AH; Carey LA
JAMA Oncol; 2024 Mar; 10(3):362-371. PubMed ID: 38236590
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.
Cisneros-Villanueva M; Fonseca-Montaño MA; Ríos-Romero M; López-Camarillo C; Jiménez-Morales S; Langley E; Rosette-Rueda AS; Cedro-Tanda A; Hernández-Sotelo D; Hidalgo-Miranda A
Sci Rep; 2024 Jan; 14(1):1483. PubMed ID: 38233470
[TBL] [Abstract] [Full Text] [Related]
15. Defining the Biology of Estrogen Receptor-Low-Positive breast cancer.
Higgins T; Kantor O; Harrison B; Giordano J; McGrath M; Burstein HJ; Schnitt SJ; Rahman T; Vora H; Garrido-Castro A; Tolaney SM; Meric-Bernstam F; King TA; Mittendorf EA
Ann Surg Oncol; 2024 Apr; 31(4):2244-2252. PubMed ID: 38161200
[TBL] [Abstract] [Full Text] [Related]
16. Genetic Ancestry-specific Molecular and Survival Differences in Admixed Patients With breast cancer.
Telonis AG; Rodriguez DA; Spanheimer PM; Figueroa ME; Goel N
Ann Surg; 2024 May; 279(5):866-873. PubMed ID: 38073557
[TBL] [Abstract] [Full Text] [Related]
17. miR-877-5p as a Potential Link between Triple-Negative breast cancer Development and Metabolic Syndrome.
Moro J; Grinpelc A; Farré PL; Duca RB; Lacunza E; Graña KD; Scalise GD; Dalton GN; Massillo C; Piccioni F; Dimase F; Batagelj E; De Siervi A; De Luca P
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069080
[TBL] [Abstract] [Full Text] [Related]
18. Homologous Recombination Deficiency Across Subtypes of Primary breast cancer.
Yndestad S; Engebrethsen C; Herencia-Ropero A; Nikolaienko O; Vintermyr OK; Lillestøl RK; Minsaas L; Leirvaag B; Iversen GT; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Aase HS; Aas T; Gudlaugsson EG; Llop-Guevara A; Serra V; Janssen EAM; Lønning PE; Knappskog S; Eikesdal HP
JCO Precis Oncol; 2023 Sep; 7():e2300338. PubMed ID: 38039432
[TBL] [Abstract] [Full Text] [Related]
19. Association of clinicopathologic and molecular factors with the occurrence of positive margins in breast cancer.
Praveen Kumar A; Vicente D; Liu J; Raj-Kumar PK; Deyarmin B; Lin X; Shriver CD; Hu H
Breast Cancer Res Treat; 2024 Feb; 204(1):15-26. PubMed ID: 38038766
[TBL] [Abstract] [Full Text] [Related]
20. Patient-specific analysis of co-expression to measure biological network rewiring in individuals.
Wei L; Xin Y; Pu M; Zhang Y
Life Sci Alliance; 2024 Feb; 7(2):. PubMed ID: 37977656
[TBL] [Abstract] [Full Text] [Related]
[Next]
